[1]丁艳艳.伏立康唑联合不同剂量泼尼松治疗变应性支气管肺曲霉病疗效观察[J].新乡医学院学报,2020,37(4):382-385.[doi:10.7683/xxyxyxb.2020.04.019]
　DING Yanyan.Effect of voriconazole combined with different doses of prednisone in the treatment of allergic bronchopulmonary aspergillosis[J].Journal of Xinxiang Medical University,2020,37(4):382-385.[doi:10.7683/xxyxyxb.2020.04.019]
点击复制

伏立康唑联合不同剂量泼尼松治疗变应性支气管肺曲霉病疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年4
页码:
382-385
栏目:
临床研究
出版日期:
2020-04-05

文章信息/Info

Title:
Effect of voriconazole combined with different doses of prednisone in the treatment of allergic bronchopulmonary aspergillosis
作者:
丁艳艳
（首都医科大学大兴教学医院呼吸与危重症医学科，北京　102600）
Author(s):
DING Yanyan
(Department of Respiratory and Critical Care Medicine，Daxing Teaching Hospital，Capital Medical University，Beijing 102600，China)
关键词:
变应性支气管肺曲霉病; 伏立康唑; 泼尼松; 肺功能; 免疫球蛋白E; 不良反应
Keywords:
allergic bronchopulmonary aspergillosis; voriconazole; prednisone; pulmonary function; immunoglobulin E; adverse reaction
分类号:
R519
DOI:
10.7683/xxyxyxb.2020.04.019
文献标志码:
A
摘要:
目的　探讨伏立康唑联合不同剂量泼尼松治疗变应性支气管肺曲霉病（ABPA）的临床效果，为ABPA的临床治疗提供参考。方法　选择2016年2月至2018年2月首都医科大学大兴教学医院收治的84例ABPA患者为研究对象，根据治疗方法将患者分为A组和B组，每组42例。2组患者均给予吸氧、抗感染、止咳平喘、化痰、支气管扩张等常规治疗，在常规治疗基础上，A组患者给予伏立康唑联合小剂量泼尼松（0.25 mg·kg-1·d-1）治疗，B组患者给予伏立康唑联合中等剂量泼尼松（0.5 mg·kg-1·d-1）治疗，2组患者均连续治疗4个月。分别于治疗前后检测患者嗜酸性粒细胞及血清总免疫球蛋白E（IgE）和烟曲霉特异性IgE水平，使用肺功能仪检测患者肺功能，记录第1秒用力呼气容积（FEV1）、FEV1与用力肺活量（FVC）的比值（FEV1/FVC）、最大呼气流量（PEF）；治疗后评估2组患者临床疗效，并观察2组患者治疗过程中不良反应发生情况。结果　2组患者治疗前嗜酸性粒细胞及血清总IgE、烟曲霉特异性IgE水平比较差异无统计学意义（P＞0.05），2组患者治疗后嗜酸性粒细胞及血清总IgE、烟曲霉特异性IgE水平显著低于治疗前（P＜0.05），2组患者治疗后嗜酸性粒细胞及血清总IgE、烟曲霉特异性IgE水平比较差异无统计学意义（P＞0.05）。2组患者治疗前FEV1、FEV1/FVC、PEF比较差异无统计学意义（P＞0.05），2组患者治疗后FEV1、FEV1/FVC、PEF显著高于治疗前（P＜0.05），2组患者治疗后FEV1、FEV1/FVC、PEF比较差异无统计学意义（P＞0.05）。A组和B组患者治疗总有效率分别为97.62%（41/42）、90.48%（38/42），2组患者治疗总有效率比较差异无统计学意义（χ2=1.914，P＞0.05）。A组和B组患者不良反应发生率分别为2.38%（1/42）、14.29%（6/42），A组患者不良反应发生率低于B组（χ2=3.896，P＜0.05）。结论　伏立康唑联合小剂量、中等剂量泼尼松治疗ABPA的疗效相当，但小剂量泼尼松的不良反应少。
Abstract:
Objective　To investigate the clinical effect of voriconazole combined with different doses of prednisone in the treatment of allergic bronchopulmonary aspergillosis (ABPA)，so as to provide a reference for clinical treatment of ABPA.Methods　A total of 84 patients with ABPA admitted to Daxing Teaching Hospital of Capital Medical University from February 2016 to February 2018 were selected as the study objects，they were divided into group A and group B according to the treatment methods，with 42 cases in each group.The patients in both groups were given routine treatment such as oxygen inhalation，anti-infection，relieving cough and asthma，dissipate phlegm and dilating bronchus.On the basis of routine treatment，the patients in group A were treated with voriconazole combined with low-dose prednisone (0.25 mg·kg-1·d-1)，and the patients in group B were treated with voriconazole combined with medium-dose prednisone (0.5 mg·kg-1·d-1).All the patients in both groups were treated for 4 months.Before and after treatment，the levels of eosinophils，serum total immunoglobulin E (IgE) and Aspergillus fumigatus specific IgE were detected;the pulmonary function of the patients was measured by pulmonary function instrument，including forced expiratory volume (FEV1)，the ratio of FEV1 to forced vital capacity (FVC) and peak expiratory flow (PEF).The clinical effect of the patients in the two groups was evaluated after treatment，and the adverse reactions were observed.Results　There was no significant difference in the levels of eosinophils，serum total IgE and Aspergillus fumigatus specific IgE between the two groups before treatment(P>0.05).The levels of eosinophils and serum total IgE and Aspergillus fumigatus specific IgE after treatment were significantly lower than those before treatment in the two groups (P<0.05).There was no significant difference in the levels of eosinophils，serum total IgE and Aspergillus fumigatus specific IgE between the two groups after treatment(P>0.05).There was no significant difference in FEV1，FEV1/FVC and PEF between the two groups before treatment (P>0.05).The FEV1，FEV1/FVC and PEF after treatment were significantly higher than those before treatment in the two groups (P<0.05).There was no significant difference in FEV1，FEV1/FVC and PEF between the two groups after treatment (P>0.05).The total effective rate in group A and group B was 97.62% (41/42) and 90.48% (38/42)，respectively.There was no significant difference in the total effective rate between the two groups (χ2　=1.914，P>0.05).The incidence of adverse reactions in group A and group B was 2.38% (1/42) and 14.29% (6/42)，respectively.The incidence of adverse reactions in group A was lower than that in group B (χ2　= 3.896，P<0.05).Conclusion　The efficacy of voriconazole combined with low-dose and medium-dose prednisone in the treatment of ABPA is similar，but the adverse reactions of low-dose prednisone are less.

参考文献/References:

［1］　张鼎，胡建，廖纪萍，等.变应性支气管肺曲霉菌病的免疫机制与诊治［J］.中华临床免疫和变态反应杂志，2015，9（2）：142-147.
［2］　DE BAETS F，DE KEYZER L，VAN DAELE S，et al.Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa-negative CF patients［J］.Pediatr Allergy Immu，2018，29(7)：726-731.
［3］　刘明伟，张卫珍，秦兰芳，等.伏立康唑治疗变态反应性支气管肺曲菌病效果分析［J］.中国老年学杂志，2016，36（10）：2513-2515.
［4］　ROVIELLO G，PETRIOLI R，BONETTA A，et al.Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone［J］.Invest New Drugs,2018,6(6):1110-1115.
［5］　中华医学会呼吸病学分会哮喘学组.变应性支气管肺曲霉病诊治专家共识［J］.中华医学杂志，2017，97（34）：2650-2656.
［6］　SINGH M，PAUL N，SINGH S，et al.Asthma and fungus：role in allergic bronchopulmonary aspergillosis (ABPA) and other conditions［J］.Indian J Pediatr,2018,85(10):899-904.
［7］　周金柱，夏皓，舒艳艳.变态反应性支气管肺曲霉菌病CT诊断分析［J］.医学影像学杂志，2015，25（6）：1106-1107.
［8］　路明，姚婉贞.变应性支气管肺曲霉病的诊治进展［J］.中华结核和呼吸杂志，2015，38（10）：770-773.
［9］　夏婷婷，徐志波，刘贤忠，等.变应性支气管肺曲霉病的诊断和治疗新进展［J］.中国医学科学院学报，2016，38（5）：611-616.
［10］　ODA N，MIYAHARA N，SENOO S，et al.Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab［J］.Allergol Int，2018,67(4):521-523.
［11］　刘自力，黄礼年.变态反应性支气管肺曲菌病诊治进展［J］.实用医学杂志，2015，31（5）：856-858.
［12］　李朋玲，王继鹏.变应性支气管肺曲菌病10例分析及文献复习［J］.中国临床研究，2016，29（8）：1117-1119，1122.
［13］　范家亮.小剂量泼尼松对极重度慢性阻塞性肺疾病患者生活质量的影响研究［J］.实用心脑肺血管病杂志，2014，22（10）：62-63.
［14］　王梦雨，乔艳俊，王红民.变应性支气管肺曲霉病26例临床分析［J］.中国呼吸与危重监护杂志，2019，18（3）：231-235.
［15］　孙文豹，米英红，张娟娟.动态肺功能测定在支气管炎与支气管哮喘中的诊断作用［J］.中国实验诊断学，2015，19（3）：401-404.

相似文献/References:

[1]毛彦娜,田　亮,刘　炜,等.不同抗真菌药物治疗儿童侵袭性肺曲霉病疗效比较[J].新乡医学院学报,2016,33(9):774.[doi:10.7683/xxyxyxb.2016.09.009]
　MAO Yan-na,TIAN Liang,LIU Wei,et al.Comparison of the effect of different antifungal medicines in treatment of children with invasive pulmonary aspergillosis[J].Journal of Xinxiang Medical University,2016,33(4):774.[doi:10.7683/xxyxyxb.2016.09.009]

更新日期/Last Update: 2020-04-05